Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
Sagimet Biosciences (NASDAQ:SGMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.
Sagimet Biosciences (NASDAQ:SGMT) is now covered by analysts at Guggenheim. They set a "buy" rating and a $27.00 price target on the stock.
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
Sagimet's Denifanstat: China Phase III Safety Data Isn't A Negative Signal [Seeking Alpha]